• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press Releases Translations

DNDi celebra iniciativa da Malásia para garantir o acesso a tratamentos mais baratos para a hepatite C

Kuala Lumpur, Malásia / Genebra, Suíça — 22 Sep 2017
  • Português
    • Português
    • English
    • Español
    • Malay

A Malásia emitiu uma licença de “uso governamental” que permite o acesso a versões mais baratas de um medicamento caro e patenteado para o tratamento da hepatite C. Essa decisão histórica deve ajudar as mais de 400 mil pessoas vivendo com hepatite C na Malásia a ter acesso ao sofosbuvir, podendo ter repercussões importantes no esforço global que é feito para garantir o acesso a caros tratamentos para esta doença.

“O governo da Malásia não pode garantir o acesso a tratamentos por causa do preço muito alto do sofosbuvir na Malásia“, disse YB Datuk Seri, Dr. S. Subramaniam, Ministro da Saúde da Malásia. “Para garantir a ampliação do nosso programa de tratamento de hepatite C, o governo quer comprar sofosbuvir genérico ao menor preço possível e disponibilizá-lo no sistema público de saúde em todo o país“.

A organização de pesquisa e desenvolvimento sem fins lucrativos Iniciativa Medicamentos para Doenças Negligenciadas (DNDi) vem realizando ensaios clínicos na Malásia, em parceria com o Ministério da Saúde e o laboratório farmacêutico egípcio Pharco Pharmaceuticals, para testar um tratamento pan-genotípico combinando sofosbuvir com o candidato a medicamento ravidasvir.

O ensaio clínico está em curso em seis hospitais com a Clinical Research Malaysia, uma entidade sem fins lucrativos de propriedade do Ministério da Saúde. A Pharco concordou em definir o preço da terapia combinada em US$ 300 por um tratamento com duração de 12 semanas, uma vez que o ravidasvir esteja registrado. Atualmente, um curso completo de tratamento está disponível na Malásia por cerca de US$ 70.000 (MYR 300.000).

“O governo da Malásia reafirmou seu forte compromisso de garantir acesso aos tratamentos para a hepatite C. A decisão também é um sinal forte para outros países onde os altos preços de tratamento atuam como uma barreira para uma abordagem de saúde pública para a hepatite C“, disse o Dr. Bernard Pécoul, Diretor Executivo da DNDi.

Normas de comércio internacional consagradas no Acordo TRIPS permitem a emissão de licenças de uso para o governo quando as empresas farmacêuticas fracassam em disponibilizar seus medicamentos patenteados a preço acessível para os pacientes.

 

Sobre DNDi

A DNDi, organização de pesquisa e desenvolvimento sem fins lucrativos, trabalha para oferecer novos tratamentos para doenças tropicais negligenciadas.

www.dndial.org / www.dndi.org

Informações para a imprensa

DNDi: Betina Moura bmoura@dndi.org Tel: +55 21 98122 2798

 
Policy advocacy Partnership Registration & access Hepatitis C

Read, watch, share

Loading...
Press releases
23 Jul 2025

AN2 Therapeutics and DNDi collaborate on clinical development of promising new oral compound to treat chronic Chagas disease

Publications
15 Jul 2025

DNDi 2024 Annual Report

Healthcare worker attending a training
Press releases
10 Jul 2025

New HIV project in the DRC brings life-saving care closer to people with advanced HIV disease

Woman working in a laboratory
News
10 Jul 2025

LEO Foundation partners with DNDi to develop breakthrough drug discovery model for mycetoma 

Press releases
1 Jul 2025

Thailand’s Government Pharmaceutical Organization (GPO) partners with DNDi and Pharco to register an effective and affordable hepatitis C treatment  

Press releases
13 Jun 2025

Serum Institute of India signs a memorandum of understanding (MoU) with DNDi to advance the development of a new treatment for dengue in low- and middle-income countries

Press releases
13 Jun 2025

K-MEDI and DNDi have initiated collaborative R&D to develop a treatment for neglected diseases

News
10 Jun 2025

Bringing life-saving care closer to people living with HIV in Kinshasa 

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License